Sofiva GenomicsLtd Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chia-Cheng Hung
Chief executive officer
NT$5.0m
Total compensation
| CEO salary percentage | 83.8% |
| CEO tenure | no data |
| CEO ownership | 2.3% |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital
Apr 14
Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)
Mar 18Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend
Feb 24Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jan 27Our Take On The Returns On Capital At Sofiva GenomicsLtd (GTSM:6615)
Jan 07
A Look At The Intrinsic Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)
Dec 15Read This Before Buying Sofiva Genomics Co.,Ltd. (GTSM:6615) For Its Dividend
Nov 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | NT$18m |
| Sep 30 2024 | n/a | n/a | NT$21m |
| Jun 30 2024 | n/a | n/a | NT$25m |
| Mar 31 2024 | n/a | n/a | NT$20m |
| Dec 31 2023 | NT$5m | NT$4m | NT$12m |
| Sep 30 2023 | n/a | n/a | NT$34m |
| Jun 30 2023 | n/a | n/a | NT$31m |
| Mar 31 2023 | n/a | n/a | NT$33m |
| Dec 31 2022 | NT$6m | NT$5m | NT$43m |
| Sep 30 2022 | n/a | n/a | NT$37m |
| Jun 30 2022 | n/a | n/a | NT$49m |
| Mar 31 2022 | n/a | n/a | NT$62m |
| Dec 31 2021 | NT$6m | NT$5m | NT$57m |
Compensation vs Market: Chia-Cheng's total compensation ($USD165.80K) is above average for companies of similar size in the TW market ($USD115.52K).
Compensation vs Earnings: Chia-Cheng's compensation has been consistent with company performance over the past year.
CEO
Chia-Cheng Hung
no data
Tenure
NT$5,012,000
Compensation
Dr. Chia-Cheng Hung is General Manager of Sofiva Genomics Co. Ltd.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 06:05 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sofiva Genomics Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Xiaowei Huang | Masterlink Securities Corp. |